Cipla has announced a JV with Kemwell Biopharma to develop and manufacture biosimilars for global markets. Biocon is a major player in biosimilars among Indian companies. The focus for the JV will be respiratory biosimilars. The JV will leverage the combined strengths in terms of product, clinical development, regulatory filings and commercialisation of biosimilars. Cipla has a strength in respiratory segment and Kemwell in biologics.
Cipla has announced a JV with Kemwell Biopharma to develop and manufacture biosimilars for global markets. Biocon is a major player in biosimilars among Indian companies. The focus for the JV will be respiratory biosimilars. The JV will leverage the combined strengths in terms of product, clinical development, regulatory filings and commercialisation of biosimilars. Cipla has a strength in respiratory segment and Kemwell in biologics.